Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease.
To examine changes in the extent of specific patterns of interstitial lung disease (ILD) as they transition from one pattern to another in response to immunosuppressive therapy of Systemic Sclerosis-related ILD. (SSc-ILD) METHODS: We evaluated changes in the quantitative extent of specific lung patterns of ILD using volumetric HRCT scans obtained at baseline and 2 years after therapy in patients treated with either cyclophosphamide (CYC) for 1 year or mycophenolate (MMF) for 2 years in the Scleroderma Lung Study II. ILD patterns included: lung fibrosis (LF), ground glass (GG), honeycombing (HC), and normal lung (NL). Net changes were calculated as the differences in the probabilities of changes from one ILD pattern to another. Wilcoxon signed-ranks tests were used to compare the changes. Forty-seven and 50 patients had baseline and follow-up scans in the CYC and MMF arms, respectively. Mean net improvements reflecting favorable changes in extent of ILD from one pattern to another in the whole lung in the CYC and MMF groups, respectively, were as follows: from LF to NL (21% and 19%), from GG to NL (30% and 28%) and from LF to GG (5% and -0.6%). Means of overall improvement in transitioning from GG or LF to NL patterns were significant for both treatments (all p<0.001). Significantly favorable transitions from both GG and LF ILD patterns to NL were found in patients undergoing immunosuppressive treatment for SSc-ILD, suggesting the usefulness of examining these transitions for insights into the underlying pathobiology of treatment response. This article is protected by copyright. All rights reserved.